Nubeqa Now Indicated for Metastatic Hormone-Sensitive Prostate Cancer

Web Exclusives - FDA Approvals

On August 5, 2022, the FDA accelerated the approval of darolutamide (Nubeqa; Bayer Healthcare), an androgen receptor inhibitor, in combination with docetaxel, for the treatment of metastatic hormone-sensitive prostate cancer in adults.

Darolutamide was previously approved for nonmetastatic castration-resistant prostate cancer.

The approval of this new indication was based on results of the randomized, multicenter, double-blind, placebo-controlled ARASENS phase 3 clinical trial of 1306 patients with metastatic hormone-sensitive prostate cancer. The patients received 600 mg of darolutamide orally twice daily plus 75 mg/m2 of docetaxel intravenously every 3 weeks for up to 6 cycles or docetaxel plus placebo.

The main end point was overall survival (OS); the secondary end point was time to pain progression. The median OS was not reached in the darolutamide arm versus 48.9 months (95% confidence interval [CI], 44.4-not reached) in the placebo arm (95% CI, 0.57-0.80; P <.0001).

Related Items
FDA Approved Izervay for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration
Web Exclusives published on September 9, 2023 in FDA Approvals
FDA Accelerated the Approval of Talvey, First Bispecific GPRC5D-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM
Web Exclusives published on September 9, 2023 in FDA Approvals
FDA Approved Xdemvy, First Treatment for Demodex Blepharitis
Web Exclusives published on September 9, 2023 in FDA Approvals
FDA Accelerated the Approval of Veopoz, First Drug for the Treatment of Patients With CHAPLE Disease
Web Exclusives published on September 9, 2023 in FDA Approvals
FDA Accelerated the Approval of Sohonos, First Drug for the Treatment of Fibrodysplasia Ossificans Progressiva
Web Exclusives published on September 9, 2023 in FDA Approvals
Last modified: December 20, 2022
© Amplity Health. All rights reserved.